High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life

被引:16
|
作者
Lin, Zhicheng [1 ,3 ]
Zhao, Ying [1 ,3 ]
Chung, Chee Yeun [2 ,4 ]
Zhou, Yanhong [1 ,3 ]
Xiong, Nian [1 ,3 ]
Glatt, Charles E. [5 ]
Isacson, Ole [2 ,4 ]
机构
[1] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02478 USA
[2] McLean Hosp, Ctr Neuroregenerat Res, Belmont, MA 02478 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA
[5] Cornell Univ, Dept Psychiat, Weill Med Coll, New York, NY 10021 USA
来源
FASEB JOURNAL | 2010年 / 24卷 / 07期
基金
美国国家卫生研究院;
关键词
human; promoter haplotypes; evolution; signaling cascades; transcription; DOPAMINE TRANSPORTER; TRANSCRIPTION FACTOR; IN-VIVO; EXPRESSION; PROMOTER; PATHWAY; VMAT2; RAT; SCHIZOPHRENIA; HAPLOTYPES;
D O I
10.1096/fj.09-140368
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates neurotransmission and reduces cytosolic toxicity of monoamines. Deletion of this gene causes lethality in mice, and DNA sequence variation in this gene is associated with alcoholism and Parkinson's disease, among other disorders. The Caucasian SLC18A2 promoter has at least 20 haplotypes (A-T), with A representing two-thirds of 1460 chromosomes. It is not known why A is selected in the human lineage. To understand the selection, here we took a functional approach by investigating the regulations of 4 representative haplotypes (A, C, G, and T) by 17 agents. We show that 76.5% of the agents were able to regulate A but only 11.8-23.5% of them regulated the 3 other infrequent ones, observing a positive correlation between haplotype frequency and regulatability. Pathway and molecular analyses revealed five signaling hubs that regulate the four haplotypes differentially, probably through targeting the polymorphic core promoter region. These findings suggest that greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2.-Lin, Z., Zhao, Y., Chung, C. Y., Zhou, Y., Xiong, N., Glatt, C. E., Isacson, O. High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life. FASEB J. 24, 2191-2200 (2010). www.fasebj.org
引用
收藏
页码:2191 / 2200
页数:10
相关论文
共 50 条
  • [11] Expression of the Vesicular Monoamine Transporter Gene Solute Carrier Family 18 Member 1 (SLC18A1) in Lung Cancer
    Lehrer, Steven
    Rheinstein, Peter H.
    CANCER GENOMICS & PROTEOMICS, 2018, 15 (05) : 387 - 393
  • [12] Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling
    Lohoff, Falk W.
    Carr, Gregory V.
    Brookshire, Bethany
    Ferraro, Thomas N.
    Lucki, Irwin
    BRAIN RESEARCH, 2019, 1712 : 151 - 157
  • [13] Variation in the vesicular monoamine transporter 1 Gene (VMAT1/SLC18A1) as risk factor for schizophrenia
    Lohoff, Falk W.
    Weller, A. E.
    Bloch, P. J.
    Buono, R. J.
    Doyle, G. A.
    Ferraro, T. N.
    Berrettini, W. H.
    NERVENARZT, 2007, 78 : 298 - 298
  • [14] Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder
    Lohoff, FW
    Dahl, JP
    Ferraro, TN
    Gallinat, J
    Sander, T
    Berrettini, WH
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2005, 138B (01) : 28 - 28
  • [15] Variations in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) are Associated with Bipolar I Disorder
    Falk W Lohoff
    John P Dahl
    Thomas N Ferraro
    Steven E Arnold
    Jürgen Gallinat
    Thomas Sander
    Wade H Berrettini
    Neuropsychopharmacology, 2006, 31 : 2739 - 2747
  • [16] Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar I disorder
    Lohoff, Falk W.
    Dahl, John P.
    Ferraro, Thomas N.
    Arnold, Steven E.
    Gallinat, Juergen
    Sander, Thomas
    Berrettini, Wade H.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (12) : 2739 - 2747
  • [17] Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1)and bipolar disorder
    Lohoff, FW
    Ferraro, TN
    Dahl, JP
    Gallinat, J
    Sander, T
    Berrettini, WH
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 65S - 65S
  • [18] Genetic and Epigenetic SLC18A2 Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy
    Sorensen, Karina Dalsgaard
    Wild, Peter Johannes
    Mortezavi, Ashkan
    Adolf, Katja
    Torring, Niels
    Heeboll, Sara
    Ulhoi, Benedicte Parm
    Ottosen, Peter
    Sulser, Tullio
    Hermanns, Thomas
    Moch, Holger
    Borre, Michael
    Orntoft, Torben Falck
    Dyrskjot, Lars
    CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1400 - 1410
  • [19] Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [18F]FP-(+)-DTBZ
    Sun, Yu
    Zhao, Ning
    Liu, Wangyuan
    Liu, Miao
    Ju, Zizhao
    Li, Jun
    Cheng, Zhen
    Liu, Xingdang
    MOLECULAR IMAGING AND BIOLOGY, 2018, 20 (05) : 771 - 779
  • [20] Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [18F]FP-(+)-DTBZ
    Yu Sun
    Ning Zhao
    Wangyuan Liu
    Miao Liu
    Zizhao Ju
    Jun Li
    Zhen Cheng
    Xingdang Liu
    Molecular Imaging and Biology, 2018, 20 : 771 - 779